Literature DB >> 9710435

Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion.

D C Devor1, B D Schultz.   

Abstract

We evaluated the acute effects of ibuprofen and salicylic acid on cAMP-mediated Cl- secretion (Isc) in both colonic and airway epithelia. In T84 cells, ibuprofen inhibited the forskolin-dependent Isc in a concentration-dependent manner, having an apparent Ki of 142 microM. Salicylic acid inhibited Isc with an apparent Ki of 646 microM. We determined whether ibuprofen would also inhibit the forskolin-stimulated Isc in primary cultures of mouse trachea epithelia (MTE) and human bronchial epithelia (HBE). Similar to our results in T84 cells, ibuprofen (500 microM) inhibited the forskolin-induced Isc in MTEs and HBEs by 59+/-4% (n = 11) and 39+/-6% (n = 8), respectively. Nystatin was employed to selectively permeabilize the basolateral or apical membrane to determine the effect of ibuprofen on apical Cl- (ICl) and basolateral K+ (IK) currents after stimulation by forskolin. After forskolin stimulation, ibuprofen (500 microM) reduced both the ICl and IK; reducing ICl and IK by 60 and 15%, respectively. To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of ibuprofen and salicylic acid on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated. Ibuprofen (300 microM) reduced CFTR Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3). Similarly, salicylic acid (3 mM) reduced CFTR Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4). Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane K+ channels. This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and/or function in secretory epithelia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710435      PMCID: PMC508929          DOI: 10.1172/JCI2614

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease.

Authors:  J T Zakrzewski; N C Barnes; J F Costello; P J Piper
Journal:  Am Rev Respir Dis       Date:  1987-09

2.  Inflammatory reaction and airway damage in cystic fibrosis.

Authors:  A D Barton; K Ryder; R V Lourenço; W Dralle; S G Weiss
Journal:  J Lab Clin Med       Date:  1976-09

Review 3.  Leukotrienes and lung disease.

Authors:  B R O'Driscoll; A B Kay
Journal:  Thorax       Date:  1982-04       Impact factor: 9.139

4.  Identification of leukotrienes D and B in sputum from cystic fibrosis patients.

Authors:  O Cromwell; M J Walport; H R Morris; G W Taylor; M E Hodson; J Batten; A B Kay
Journal:  Lancet       Date:  1981-07-25       Impact factor: 79.321

Review 5.  Proteases and lung injury. A state-of-the-art minireview.

Authors:  A Janoff
Journal:  Chest       Date:  1983-05       Impact factor: 9.410

6.  Leukocytes in lung injury.

Authors:  D E Hammerschmidt
Journal:  Chest       Date:  1983-05       Impact factor: 9.410

7.  Activation of a 15-lipoxygenase/leukotriene pathway in human polymorphonuclear leukocytes by the anti-inflammatory agent ibuprofen.

Authors:  J Y Vanderhoek; J M Bailey
Journal:  J Biol Chem       Date:  1984-06-10       Impact factor: 5.157

8.  Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

Authors:  H S Auerbach; M Williams; J A Kirkpatrick; H R Colten
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

9.  Ibuprofen modifies the inflammatory response of the murine lung to Pseudomonas aeruginosa.

Authors:  D O Sordelli; M C Cerquetti; G el-Tawil; P W Ramwell; A M Hooke; J A Bellanti
Journal:  Eur J Respir Dis       Date:  1985-08

10.  Cl(-)-channel blockers in the thick ascending limb of the loop of Henle. Structure activity relationship.

Authors:  P Wangemann; M Wittner; A Di Stefano; H C Englert; H J Lang; E Schlatter; R Greger
Journal:  Pflugers Arch       Date:  1986       Impact factor: 3.657

View more
  9 in total

1.  The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential.

Authors:  Manish Bodas; Neeraj Vij
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

2.  Multiple action sites of flufenamate on ion transport across the rat distal colon.

Authors:  G Schultheiss; M Frings; G Hollingshaus; M Diener
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

3.  CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells.

Authors:  Neeraj Vij; Martha O Amoako; Steven Mazur; Pamela L Zeitlin
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-20       Impact factor: 6.914

4.  Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in Xenopus oocytes.

Authors:  Marina N Chernova; Lianwei Jiang; Boris E Shmukler; Clifford W Schweinfest; Paola Blanco; Steven D Freedman; Andrew K Stewart; Seth L Alper
Journal:  J Physiol       Date:  2003-03-21       Impact factor: 5.182

5.  Aspirin and some other nonsteroidal anti-inflammatory drugs inhibit cystic fibrosis transmembrane conductance regulator protein gene expression in T-84 cells.

Authors:  D Tondelier; F Brouillard; J Lipecka; R Labarthe; M Bali; M A Costa de Beauregard; T Torossi; M Cougnon; A Edelman; M Baudouin-Legros
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

6.  Drug repositioning can accelerate discovery of pharmacological chaperones.

Authors:  Bruno Hay Mele; Valentina Citro; Giuseppina Andreotti; Maria Vittoria Cubellis
Journal:  Orphanet J Rare Dis       Date:  2015-05-07       Impact factor: 4.123

7.  Inhibition of cAMP-activated intestinal chloride secretion by diclofenac: cellular mechanism and potential application in cholera.

Authors:  Pawin Pongkorpsakol; Nutthapoom Pathomthongtaweechai; Potjanee Srimanote; Sunhapas Soodvilai; Varanuj Chatsudthipong; Chatchai Muanprasat
Journal:  PLoS Negl Trop Dis       Date:  2014-09-04

8.  New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis.

Authors:  Jérémy Rocca; Sylvie Manin; Anne Hulin; Abdel Aissat; Wilfried Verbecq-Morlot; Virginie Prulière-Escabasse; Adeline Wohlhuter-Haddad; Ralph Epaud; Pascale Fanen; Agathe Tarze
Journal:  Br J Pharmacol       Date:  2016-04-21       Impact factor: 8.739

9.  Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis.

Authors:  Luigina Romani; Vasilis Oikonomou; Silvia Moretti; Rossana G Iannitti; Maria Cristina D'Adamo; Valeria R Villella; Marilena Pariano; Luigi Sforna; Monica Borghi; Marina M Bellet; Francesca Fallarino; Maria Teresa Pallotta; Giuseppe Servillo; Eleonora Ferrari; Paolo Puccetti; Guido Kroemer; Mauro Pessia; Luigi Maiuri; Allan L Goldstein; Enrico Garaci
Journal:  Nat Med       Date:  2017-04-10       Impact factor: 53.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.